A Migraine Treatment Starts Working in Just 10 Minutes
- The Big Discovery: A preventive migraine drug can start easing pain and light sensitivity during an ongoing attack—in as little as 10 minutes.
- Who it helps: People with frequent episodic or chronic migraine who are getting an intravenous (IV) infusion of the drug eptinezumab.
- The Catch: This was a small, preliminary study. The drug is already approved for prevention, but using it during an attack is a new, off-label approach.
Migraine is not just a bad headache. It’s a complex neurological disease. For millions, it means severe, throbbing pain often paired with nausea, and extreme sensitivity to light and sound.
Preventive treatments aim to reduce how often attacks happen. But when a migraine strikes, patients rely on “acute” medications to stop it. These don’t work for everyone, and overuse can lead to more headaches.
The search has always been for treatments that are both preventive and fast-acting. This new study hints at a possible two-for-one effect.
The Surprising Shift in Timing
Eptinezumab is a preventive drug. It’s an antibody given by IV every three months. It works by blocking a protein in the brain called CGRP, which is involved in migraine pain signals. Doctors and patients expected it to work slowly, over weeks, to reduce future attacks.
But what if it could also put out a fire that’s already burning?
This study asked that exact question. Researchers gave eptinezumab to patients who were already in the middle of a migraine attack. They watched to see what would happen during the infusion itself.
Think of CGRP as a master alarm bell for migraine pain. When it’s ringing, pain signals flood the brain, causing the attack.
Preventive CGRP blockers like eptinezumab are like installing a permanent mute button on that alarm over time. This new research suggests that when you flood the system with this “mute button” antibody during an active attack, it might start silencing the alarm almost immediately.
It doesn’t just prevent the next ring. It quiets the current clanging.
A Snapshot of the Study
The Italian BE-FREE study included 31 patients with frequent migraines. All were having a migraine attack when they arrived for their scheduled eptinezumab infusion. Researchers measured their pain and symptoms right before the IV started and then every 10 minutes.
They tracked the first half-hour of the infusion in real time.
The Speed Was Unprecedented
The results were striking. Patients reported a significant drop in pain intensity at just 10 and 20 minutes into the infusion.
Sensitivity to light improved at 10 minutes. Sensitivity to sound got better at 20 minutes. By 30 minutes, nearly one-third of patients (29%) were completely pain-free.
This is where it gets interesting.
These changes happened while the drug was still dripping into their veins. This is a speed previously associated only with powerful acute treatments, not a quarterly preventive.
A Cautious Expert Perspective
This is the first real-world evidence of such a rapid effect. It shifts how we might think about this class of drugs. It suggests the line between prevention and acute treatment could be blurrier than we thought.
The lead researcher noted this opens new questions about how these antibodies work in the brain during an active attack.
What This Means For You Today
It is critical to understand this does not mean you should ask for an IV infusion the next time you have a migraine.
Eptinezumab is approved by the FDA for the prevention of migraine. Using it as an acute treatment during an attack is an “off-label” use observed in this small study. It is not standard practice.
If you are already on eptinezumab and get a migraine around your infusion time, this data is reassuring. Your treatment may help more quickly than you expected. Always discuss any changes in your symptoms with your neurologist.
The Study's Limitations
This was a small, preliminary study with only 31 patients. There was no comparison group receiving a placebo infusion. Larger, controlled studies are needed to confirm these dramatic early effects and understand how common they are.
These promising early results will spur more research. Scientists will need to run larger clinical trials specifically designed to test eptinezumab as an acute treatment. They’ll need to confirm the effect, find the right dose, and see which patients benefit most.
The path from intriguing observation to approved treatment is long and requires rigorous testing. For now, this study offers a powerful new insight: the medicine that prevents your next migraine might also be able to rescue you from your current one faster than anyone imagined.